{"id":1708,"date":"2025-09-25T17:36:24","date_gmt":"2025-09-25T15:36:24","guid":{"rendered":"https:\/\/salvia.de\/?p=1708"},"modified":"2026-02-25T17:37:56","modified_gmt":"2026-02-25T16:37:56","slug":"bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001","status":"publish","type":"post","link":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/","title":{"rendered":"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001"},"content":{"rendered":"<blockquote class=\"wp-embedded-content\" data-secret=\"K9xdM4aG0d\"><p><a href=\"https:\/\/bambusatx.com\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\">Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001&#8221; &#8212; Bambusa Therapeutics\" src=\"https:\/\/bambusatx.com\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/embed\/#?secret=kr8OSCpcEJ#?secret=K9xdM4aG0d\" data-secret=\"K9xdM4aG0d\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[30],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH\" \/>\n<meta property=\"og:url\" content=\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\" \/>\n<meta property=\"og:site_name\" content=\"Salvia GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-25T15:36:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T16:37:56+00:00\" \/>\n<meta name=\"author\" content=\"Salvia GmbH\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Salvia GmbH\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\",\"url\":\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\",\"name\":\"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH\",\"isPartOf\":{\"@id\":\"https:\/\/salvia.de\/#website\"},\"datePublished\":\"2025-09-25T15:36:24+00:00\",\"dateModified\":\"2026-02-25T16:37:56+00:00\",\"author\":{\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c\"},\"breadcrumb\":{\"@id\":\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/salvia.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/salvia.de\/#website\",\"url\":\"https:\/\/salvia.de\/\",\"name\":\"Salvia GmbH\",\"description\":\"Wir unterst\u00fctzen heute innovative Unternehmen von morgen mit Kapital, Know-how und Netzwerk.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/salvia.de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c\",\"name\":\"Salvia GmbH\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/salvia.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g\",\"caption\":\"Salvia GmbH\"},\"url\":\"https:\/\/salvia.de\/en\/author\/salvia-gmbh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/","og_locale":"en_US","og_type":"article","og_title":"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH","og_url":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/","og_site_name":"Salvia GmbH","article_published_time":"2025-09-25T15:36:24+00:00","article_modified_time":"2026-02-25T16:37:56+00:00","author":"Salvia GmbH","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Salvia GmbH","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/","url":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/","name":"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001 - Salvia GmbH","isPartOf":{"@id":"https:\/\/salvia.de\/#website"},"datePublished":"2025-09-25T15:36:24+00:00","dateModified":"2026-02-25T16:37:56+00:00","author":{"@id":"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c"},"breadcrumb":{"@id":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/salvia.de\/en\/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/salvia.de\/en\/"},{"@type":"ListItem","position":2,"name":"Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001"}]},{"@type":"WebSite","@id":"https:\/\/salvia.de\/#website","url":"https:\/\/salvia.de\/","name":"Salvia GmbH","description":"Wir unterst\u00fctzen heute innovative Unternehmen von morgen mit Kapital, Know-how und Netzwerk.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/salvia.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/salvia.de\/#\/schema\/person\/3af210793101a618e4cab377f5d7585c","name":"Salvia GmbH","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/salvia.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d76f3c6a335d5aadaa80deb8f13de078?s=96&d=mm&r=g","caption":"Salvia GmbH"},"url":"https:\/\/salvia.de\/en\/author\/salvia-gmbh\/"}]}},"_links":{"self":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1708"}],"collection":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/comments?post=1708"}],"version-history":[{"count":1,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1708\/revisions"}],"predecessor-version":[{"id":1709,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/posts\/1708\/revisions\/1709"}],"wp:attachment":[{"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/media?parent=1708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/categories?post=1708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/salvia.de\/en\/wp-json\/wp\/v2\/tags?post=1708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}